Pleiotropic effects of sevelamer beyond phosphate binding in end-stage renal disease patients: A randomized, open-label, parallel-group study

Clinical Drug Investigation

Volumn 31, Issue 4, 2011, Pages 257-267

  Lin, Yu Feng ^a   Chien, Chiang Ting ^b   Kan, Wei Chih ^c   Chen, Yung Ming ^a   Chu, Tzong Shinn ^a   Hung, Kuan Yu ^a   Tsai, Tun Jun ^a   Wu, Kwan Dun ^a   Wu, Ming Shiou ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Calcium acetate, therapeutic use; Haemodialysis; Renal failure; Sevelamer, therapeutic use

Indexed keywords

CALCIUM; CALCIUM ACETATE; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHORUS; REACTIVE OXYGEN METABOLITE; SEVELAMER; URIC ACID;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CONSTIPATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; OXIDATIVE STRESS; PHOSPHATE BLOOD LEVEL; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URIC ACID BLOOD LEVEL;

ADULT; AGED; CALCIUM; CHELATING AGENTS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MIDDLE AGED; PHOSPHORUS; POLYAMINES; REACTIVE OXYGEN SPECIES; RENAL DIALYSIS; URIC ACID;

EID: 79952389123     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11539120-000000000-00000     Document Type: Article

References (42)

1. Stel VS, van Dijk PC, van Manen JG, et al. Prevalence of comorbidity in different European RRT populations and its effect on access to renal transplantation. Nephrol Dial Transplant 2005; 20 (12): 2803-11 (Pubitemid 41672283)
2. Goodman WG, Goldin J, Kuizon BD, et al. Coronaryartery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000 May 18; 342 (20): 1478-83 (Pubitemid 30318271)
3. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998 Apr; 31 (4): 607-17
4. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002 Nov; 62 (5): 1524-38 (Pubitemid 35286260)
5. Drueke TB, Nguyen Khoa T, Massy ZA, et al. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int Suppl. 2001 Feb; 78: S114-9 (Pubitemid 32144082)
6. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001 Nov 27; 104 (22): 2673-8 (Pubitemid 33108132)
7. Mezzano D, Pais EO, Aranda E, et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001 Nov; 60 (5): 1844-50 (Pubitemid 32999989)
8. Bhatt DL. Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention.AmJ Cardiol 2008 May 22; 101 (10A): 4D-13D
9. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997 Jan; 29 (1): 66-71 (Pubitemid 27020797)
10. Hervas JG, Prados D, Cerezo S. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Kidney Int 2003 Jun; (85 Suppl.): S69-72 (Pubitemid 36605867)
11. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004 May; 65 (5): 1914-26 (Pubitemid 38591044)
12. Phan O, Ivanovski O, Nguyen-Khoa T, et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005 Nov 1; 112 (18): 2875-82 (Pubitemid 41641683)
13. Faulkner K, Fridovich I. Luminol and lucigenin as detectors for O2. Free Radic Biol Med 1993 Oct; 15 (4): 447-51
14. Huang KC, Yang CC, Lee KT, et al. Reduced hemodialysisinduced oxidative stress in end-stage renal disease patients by electrolyzed reduced water. Kidney Int 2003 Aug; 64 (2): 704-14
15. Cheng YJ, Chan KC, Chien CT, et al. Oxidative stress during 1-lung ventilation. J Thorac Cardiovasc Surg 2006 Sep; 132 (3): 513-8
16. Cheng YJ, Chien CT, Chen CF. Oxidative stress in bilateral total knee replacement, under ischaemic tourniquet. J Bone Joint Surg Br 2003 Jul; 85 (5): 679-82
17. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000 Jun; 35 (6): 1226-37 (Pubitemid 30354431)
18. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996 Mar; 27 (3): 394-401 (Pubitemid 26075849)
19. Goodman WG, London G, Amann K, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004 Mar; 43 (3): 572-9 (Pubitemid 38298218)
20. Ribeiro S, Ramos A, Brandao A, et al. Cardiac valve calcification in haemodialysis patients: role of calciumphosphate metabolism. Nephrol Dial Transplant 1998 Aug; 13 (8): 2037-40 (Pubitemid 28356772)
21. Wang AY, Wang M, Woo J, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003 Jan; 14 (1): 159-68 (Pubitemid 36032720)
22. Moe SM, Duan D, Doehle BP, et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003 Mar; 63 (3): 1003-11 (Pubitemid 36315578)
23. Tschope W, Koch M, Thomas B, et al. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis: results of a prospective study. The German Study Group Diabetes and Uremia. Nephron 1993; 64 (3): 354-8 (Pubitemid 23202840)
24. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease.NEngl JMed 2005 Apr 21; 352 (16): 1685-95
25. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001 Feb 23; 104 (4): 503-16 (Pubitemid 32201946)
26. Achenbach S, Ropers D, Pohle K, et al. Influence of lipidlowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002 Aug 27; 106 (9): 1077-82 (Pubitemid 34970847)
27. Callister TQ, Raggi P, Cooil B, et al. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998 Dec 31; 339 (27): 1972-8 (Pubitemid 29024129)
28. Takei T, Otsubo S, Uchida K, et al. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract 2008;108 (4): c278-83 (Pubitemid 351704301)
29. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on longterm dialysis. N Engl J Med 1998 Sep 17; 339 (12): 799-805 (Pubitemid 28447453)
30. Ohno I, Yamaguchi Y, Saikawa H, et al. Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Intern Med 2009; 48 (6): 415-20
31. Alderman MH, Cohen H, Madhavan S, et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999 Jul; 34 (1): 144-50 (Pubitemid 29325733)
32. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 995-1003 (Pubitemid 34286536)
33. Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000 Aug; 18 (8): 1149-54
34. Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart- disease Evaluation (GREACE) study. Am J Kidney Dis 2004 Apr; 43 (4): 589-99 (Pubitemid 38401873)
35. Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004 Mar; 65 (3): 1041-9 (Pubitemid 38251080)
36. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008 Oct 23; 359 (17): 1811-21
37. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003 Jun; 41 (6): 1287-93 (Pubitemid 36706079)
38. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002 Dec; 13 (12): 2888-97 (Pubitemid 35386908)
39. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebocontrolled studies. Circulation 2002 Jun 4; 105 (22): 2619-24 (Pubitemid 34596038)
40. Jung O, Marklund SL, Geiger H, et al. Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSODdeficient mice. Circ Res 2003 Oct 3; 93 (7): 622-9 (Pubitemid 37222158)
41. Griendling KK, Sorescu D, Lassegue B, et al. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000 Oct; 20 (10): 2175-83
42. Ushio-Fukai M, Alexander RW, Akers M, et al. p38 Mitogen- activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II: role in vascular smooth muscle cell hypertrophy. J Biol Chem 1998 Jun 12; 273 (24): 15022-9 (Pubitemid 28272796)